• Prophylactic Radical Fimbriectomy with Delayed Oophorectomy in Women with a High Risk of Developing an Ovarian Carcinoma: Results of a Prospective National Pilot Study.
    • Leblanc E, Narducci F, Ferron G, Mailliez A, Charvolin JY, El Hajj H, Guyon F, Fourchotte V, Lambaudie E, Crouzet A, Fouche Y, Gouy S, Collinet P, Caquant F, Pomel C, Golfier F, Vaini-Cowen V, Fournier I, Salzet M, Tresch E, Probst A, Lemaire AS, Le Deley MC, Hudry D.
    • Cancers (Basel). 2023 Feb 10;15(4):1141. doi: 10.3390/cancers15041141.

    •• Identifier: NCT01608074: Radical Fimbriectomy for Young BRCA Mutation Carriers (Fimbriectomy). (ClinicalTrials.gov . Accessed 2023 Feb 12.)

    • A questionnaire-based survey on the diagnostic and therapeutic approaches for patients with STIC in Germany.
    • van der Ven J, Linz VC, Anic K, Schmidt MW, Loewe A, Krajnak S, Schmidt M, Kommoss S, Schmalfeldt B, Sehouli J, Hasenburg A, Battista MJ.
    • Arch Gynecol Obstet. 2023 Jan 27. doi: 10.1007/s00404-023-06919-8. Epub ahead of print.
    • Pathologic Findings at Risk Reducing Surgery in BRCA and Non-BRCA Mutation Carriers: A Single-Center Experience.
    • Cassani C, Rossi C, Camnasio CA, Urtis M, Fiandrino G, Grasso M, Zanellini F, Lucioni M, D’Ambrosio G, Di Toro A, Rossi M, Roccio M, Ferrari A, Secondino S, Nappi RE, Arbustini E, Paulli M, Spinillo A, Cesari S.
    • Diagnostics (Basel). 2022 Dec 6;12(12):3054. doi: 10.3390/diagnostics12123054.
    • Frequency of serous tubal intraepithelial carcinoma (STIC) in patients with high grade serous ovarian cancer.
    • Byun JM, Cho HJ, Lee DS, Yoon HK, Kim YN, Im DH, Kim DH, Lee KB, Sung MS, Jeong DH.
    • Taiwan J Obstet Gynecol. 2023 Jan;62(1):107-111. doi: 10.1016/j.tjog.2022.09.006.
    • Considerations for the Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy.
    • Zhang J, Liu M.
    • J Clin Oncol. 2022 Nov 10;40(32):3783. doi: 10.1200/JCO.22.00726. Epub 2022 Jul 12.

    •• Original research:

    Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis.

    •• Reply, Letter:

    Reply to J. Zhang et al.

    • The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2.
    • Philpott S, Raikou M, Manchanda R, Lockley M, Singh N, Scott M, Evans DG, Adlard J, Ahmed M, Edmondson R, Woodward ER, Lamnisos A, Balega J, Brady AF, Sharma A, Izatt L, Kulkarni A, Tripathi V, Solomons JS, Hayes K, Hanson H, Snape K, Side L, Skates S, McGuire A, Rosenthal AN.
    • J Med Genet. 2022 Nov 1:jmedgenet-2022-108741. doi: 10.1136/jmg-2022-108741. Epub ahead of print.
    • Outcome and management of STIC following opportunistic salpingectomy: systematic review and meta-analysis.
    • Ruel-Laliberté J, Kasasni SM, Oprea D, Viau M.
    • J Obstet Gynaecol Can. 2022 Sep 10:S1701-2163(22)00612-0. doi: 10.1016/j.jogc.2022.08.018. Epub ahead of print.
    • Meta-Analysis
    • Peritoneal dissemination of high-grade serous ovarian cancer: pivotal roles of chromosomal instability and epigenetic dynamics.
    • Konishi I, Abiko K, Hayashi T, Yamanoi K, Murakami R, Yamaguchi K, Hamanishi J, Baba T, Matsumura N, Mandai M; Kyoto Study Group for Ovarian Cancer Research.
    • J Gynecol Oncol. 2022 Sep;33(5):e83. doi: 10.3802/jgo.2022.33.e83.
    • A prospective multicentric study of risk-reducing salpingo-oophorectomy in BRCA mutation patients.
    • Loizzi V, Cicinelli E, Del Vecchio V, Arezzo F, Deromemaj X, Kardhashi A, Paradiso A, Legge F, Natalicchio MI, Resta L, Resta N, Loconte DC, Cormio G.
    • Acta Biomed. 2022 Aug 31;93(4):e2022051. doi: 10.23750/abm.v93i4.11695.
    • Incidence of pelvic high-grade serous carcinoma after isolated STIC diagnosis: A systematic review of the literature.
    • Linz VC, Löwe A, van der Ven J, Hasenburg A, Battista MJ.
    • Front Oncol. 2022 Aug 31;12:951292. doi: 10.3389/fonc.2022.951292.
    • Changing patterns of referral into a family history clinic and detection of ovarian cancer: a retrospective 10-year review.
    • Smallwood KG, Crockett S, Huang V, Cullimore V, Davies J, Satti G, Phillips A.
    • J Obstet Gynaecol. 2022 Aug 18:1-7. doi: 10.1080/01443615.2022.2111253. Epub ahead of print.
    • Satisfaction and Quality of Life of Healthy and Unilateral Diseased BRCA1/2 Pathogenic Variant Carriers after Risk-Reducing Mastectomy and Reconstruction Using the BREAST-Q Questionnaire.
    • Herold N, Hellmich M, Lichtenheldt F, Ataseven B, Hillebrand V, Wappenschmidt B, Schmutzler RK, Rhiem K.
    • Genes (Basel). 2022 Jul 28;13(8):1357. doi: 10.3390/genes13081357.
    • Risk reducing surgery with peritoneal staging in BRCA1-2 mutation carriers. A prospective study.
    • Marchetti C, Arcieri M, Vertechy L, Ergasti R, Russo G, Zannoni GF, Minucci A, Ercoli A, Scambia G, Fagotti A.
    • Eur J Surg Oncol. 2022 Jul 19:S0748-7983(22)00549-2. doi: 10.1016/j.ejso.2022.07.007. Epub ahead of print.
    • TP53 variants in p53 signatures and the clonality of STICs in RRSO samples.
    • Akahane T, Masuda K, Hirasawa A, Kobayashi Y, Ueki A, Kawaida M, Misu K, Nakamura K, Nagai S, Chiyoda T, Yamagami W, Hayashi S, Kataoka F, Banno K, Sugano K, Okita H, Kosaki K, Nishihara H, Aoki D.
    • J Gynecol Oncol. 2022 Jul;33(4):e50. doi: 10.3802/jgo.2022.33.e50. Epub 2022 Mar 21.
    • Genomic catastrophe, the peritoneal cavity and ovarian cancer prevention.
    • Yoon JY, Chapel DB, Goebel E, Qian X, Mito JK, Horowitz NS, Miron A, Soong TR, Xian W, Crum CP.
    • J Pathol. 2022 Jul;257(3):255-261. doi: 10.1002/path.5891. Epub 2022 Apr 18.
    • Review
    • What Chris Evert’s Story Can Teach the World about Genetic Testing.
    • Matloff ET.
    • FORCE. Blog. 2022 Jun 22.
    • Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis.
    • Steenbeek MP, van Bommel MHD, Bulten J, Hulsmann JA, Bogaerts J, Garcia C, Cun HT, Lu KH, van Beekhuizen HJ, Minig L, Gaarenstroom KN, Nobbenhuis M, Krajc M, Rudaitis V, Norquist BM, Swisher EM, Mourits MJE, Massuger LFAG, Hoogerbrugge N, Hermens RPMG, IntHout J, de Hullu JA.
    • J Clin Oncol. 2022 Jun 10;40(17):1879-1891. doi: 10.1200/JCO.21.02016. Epub 2022 Mar 18.
    • Meta-Analysis

    •• Commentary:

    Risk of Peritoneal Cancer After Risk-Reducing Bilateral Salpingo-Oophorectomy for Women With Germline BRCA Pathogenic Variants: A Cause for Concern or Potentially Avoidable?

    •• Letter, Commentary:

    Considerations for the Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy.

    •• Reply, Letter:

    Reply to J. Zhang et al.

    • Protocol for the Detection of Organoid-Initiating Cell Activity in Patient-Derived Single Fallopian Tube Epithelial Cells.
    • Feng L, Yang W, Zhao H, Bakkum-Gamez J, Sherman ME, Kannan N.
    • Methods Mol Biol. 2022 [First Online: 2022 May 5];2429:445-454. doi: 10.1007/978-1-0716-1979-7_30.
    • Screening and risk reducing surgery for endometrial or ovarian cancers in Lynch syndrome: a systematic review.
    • Lim N, Hickey M, Young GP, Macrae FA, Kelly C.
    • Int J Gynecol Cancer. 2022 May 3;32(5):646-655. doi: 10.1136/ijgc-2021-003132.
    • Fallopian Tube Originating Ovarian Cancer in a 53-Year-Old Postmenopausal Female With Hereditary Breast Cancer (BRCA) Genes: A Case Study.
    • Garrick I, Ahasan H, Jiang M, Musheyev Y, Ftiha F, Levada M.
    • Cureus. 2022 Apr 7;14(4):e23929. doi: 10.7759/cureus.23929.
    • Recommendations for diagnosing STIC: a systematic review and meta-analysis.
    • Bogaerts JMA, Steenbeek MP, van Bommel MHD, Bulten J, van der Laak JAWM, de Hullu JA, Simons M.
    • Virchows Arch. 2022 Apr;480(4):725-737. doi: 10.1007/s00428-021-03244-w. Epub 2021 Dec 1.
    • Focal Serous Tubal Intra-Epithelial Carcinoma Lesions Are Associated With Global Changes in the Fallopian Tube Epithelia and Stroma.
    • Wu J, Raz Y, Recouvreux MS, Diniz MA, Lester J, Karlan BY, Walts AE, Gertych A, Orsulic S.
    • Front Oncol. 2022 Mar 21;12:853755. doi: 10.3389/fonc.2022.853755.
    • Computerized morphometry analysis of epithelial fimbriae nuclear symmetry in BRCA carriers may identify patients at risk for developing ovarian cancer.
    • Amit A, Sabo E, Petruseva A, Stroller L, Reiss A, Klorin G.
    • Microsc Res Tech. 2022 Mar;85(3):892-899. doi: 10.1002/jemt.23958. Epub 2021 Oct 9.
    • Serous Tubal Intraepithelial Carcinoma in a Risk-reducing Salpingo-oophorectomy Specimen From a RAD51D Mutation Carrier: A Case Report.
    • Gregory-Davis KJ, Walker A, Colello LS, McKinnon W, Everett E, Chang MC.
    • Int J Gynecol Pathol. 2022 Feb 11. doi: 10.1097/PGP.0000000000000857. Epub ahead of print.
    • Case report
    • Chris Evert's ovarian cancer diagnosis highlights the importance of genetic counseling and testing.
    • [No author given]
    • FORCE. XRAY. 2022 Feb 8.

    Press: Chris Evert opens up about her stage 1C ovarian cancer diagnosis. (ESPN)

    • Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking beyond BRCA1 and BRCA2.
    • Samuel D, Diaz-Barbe A, Pinto A, Schlumbrecht M, George S.
    • Cells. 2022 Feb 4;11(3):539. doi: 10.3390/cells11030539.
    • Long-term tumour dormancy in a BRCA1 heterozygote.
    • Amuzu S, Fu L, Demko N, Rivera B, Domecq C, de Kock L, Hamel N, Gilbert L, Polak P, Ragoussis J, Foulkes WD.
    • J Med Genet. 2022 Jan 17:jmedgenet-2021-108269. doi: 10.1136/jmedgenet-2021-108269. Epub ahead of print.
    • Case report
    • Chris Evert opens up about her stage 1C ovarian cancer diagnosis.
    • McKendry C, Evert C.
    • ESPN. 2022 Jan 14.

    News: Chris Evert's ovarian cancer diagnosis highlights the importance of genetic counseling and testing. (FORCE. XRAY.)

    • Tubal histopathological abnormalities in BRCA1/2 mutation carriers undergoing prophylactic salpingo-oophorectomy: a case-control study.
    • Sina F, Cassani C, Comerio C, De Ponti E, Zanellini F, Delle Marchette M, Roversi G, Jaconi M, Arbustini E, Urtis M, Dell'Oro C, Zambetti B, Paniga C, Acampora E, Negri S, Lazzarin S, Cesari S, Spinillo A, Kotsopoulos J, Fruscio R.
    • Int J Gynecol Cancer. 2022 Jan;32(1):41-47. doi: 10.1136/ijgc-2021-003153. Epub 2021 Nov 29.
    • Evidence for Diverse Prognosis in High-Grade Serous Ovarian Carcinoma: Solid, Pseudoendometrioid, and Transitional-Like; So-Called "SET Morphology" and Progesterone Receptor Status.
    • Uner H, Demir M, Goksuluk D, Kars A, Uner M, Usubutun A.
    • Turk Patoloji Derg. 2022;38(3):240-250. English. doi: 10.5146/tjpath.2022.01571.
    • Metastatic ovarian carcinoma in breast cancer patients during risk-reducing salpingo-oophorectomy: Report of two cases.
    • Shakya P, Bajracharya A, Shrestha S, Kharel S, Maharjan R, Shrestha AK.
    • Ann Med Surg (Lond). 2021 Dec 6;73:103158. doi: 10.1016/j.amsu.2021.103158. eCollection 2022 Jan.
    • Uptake Rate of Risk-Reducing Salpingo-Oophorectomy and Surgical Outcomes of Female Germline BRCA1/2 Mutation Carriers: A Retrospective Cohort Study.
    • Lim H, Kim SI, Hyun S, Lee GB, Seol A, Lee M.
    • Yonsei Med J. 2021 Dec;62(12):1090-1097. doi: 10.3349/ymj.2021.62.12.1090.
    • The challenging screen detection of ovarian cancer in BRCA mutation carriers adhering to a 6-month follow-up program: results from a 6-years surveillance.
    • Grandi G, Fiocchi F, Cortesi L, Toss A, Boselli F, Sammarini M, Sighinolfi G, Facchinetti F.
    • Menopause. 2021 Nov 1;29(1):63-72. doi: 10.1097/GME.0000000000001883.
    • Efficacy of risk-reducing salpingo-oophorectomy in BRCA1-2 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC).
    • Saccardi C, Zovato S, Spagnol G, Bonaldo G, Marchetti M, Alessandrini L, Tognazzo S, Guerriero A, Vitagliano A, Laganà AS, Noventa M.
    • Gynecol Oncol. 2021 Nov;163(2):364-370. doi: 10.1016/j.ygyno.2021.08.021. Epub 2021 Aug 28.
    • Profile of Pathogenic Mutations and Evaluation of Germline Genetic Testing Criteria in Consecutive Breast Cancer Patients Treated at a North Indian Tertiary Care Center.
    • Mittal A, Deo SVS, Gogia A, Batra A, Kumar A, Bhoriwal S, Deb KS, Dhamija E, Thulkar S, Ramprasad VL, Olopade O, Pramanik R.
    • Ann Surg Oncol. 2021 Oct 2:1–10. doi: 10.1245/s10434-021-10870-w. Epub ahead of print.
    • Role of Routine Peritoneal Biopsies During Risk Reducing Salpingo-Oophorectomy (RRSO).
    • Pross T, Karsten MM, Blohmer JU, Speiser D.
    • Geburtshilfe Frauenheilkd. 2021 Sep;81(9):1031-1038. doi: 10.1055/a-1395-7715. Epub 2021 Sep 13.
    • Clinical and pathological outcomes of risk-reducing salpingo-oophorectomy for Japanese women with hereditary breast and ovarian cancer.
    • Nomura H, Ikki A, Fusegi A, Omi M, Aoki Y, Netsu S, Tanigawa T, Matoda M, Okamoto S, Omatsu K, Nakajima T, Ueki A, Tonooka A, Kanao H.
    • Int J Clin Oncol. 2021 Aug 28. doi: 10.1007/s10147-021-02020-9. Epub ahead of print.
    • Follow-up of tissue genomics in BRCA1/2 carriers who underwent prophylactic surgeries.
    • Kotoula V, Papadopoulou K, Tikas I, Fostira F, Vrettou E, Chrisafi S, Fountzilas E, Koliou GA, Apostolou P, Papazisis K, Zaramboukas T, Asimaki-Vlachopoulou A, Miliaras S, Ananiadis A, Poulios C, Natsiopoulos I, Tsiftsoglou A, Demiri E, Fountzilas G.
    • Breast Cancer. 2021 Jul 24. doi: 10.1007/s12282-021-01276-3. Epub ahead of print.
    • Changes in Stem Cell Regulation and Epithelial Organisation during Carcinogenesis and Disease Progression in Gynaecological Malignancies.
    • Cunnea P, Fotopoulou C, Ploski J, Trillsch F, Mahner S, Kessler M.
    • Cancers (Basel). 2021 Jul 3;13(13):3349. doi: 10.3390/cancers13133349.
    • Risk of epithelial ovarian cancer Type I and II after hysterectomy, salpingectomy and tubal ligation - A nationwide case control study.
    • Darelius A, Kristjansdottir B, Dahm-Kähler P, Strandell A.
    • Int J Cancer. 2021 Jun 21. doi: 10.1002/ijc.33714. Epub ahead of print.
    • Gynecological lesions in hereditary cancer predisposition syndromes.
    • Dundr P, Cibula D, Foretová L, Macek M Jr, Kopecková K, Petruželka L, Nemejcová K, Bártu M, Hojný J, Hájková N, Jakša R, Janega P, Stružinská I.
    • Cesk Patol. 2021 Summer;57(2):96-104. English.
    • Ovarian cancer arising from the proximal fallopian tube in a patient with a BRCA2 mutation.
    • Badiner N, Nchako CM, Ma L, Frey MK.
    • Gynecol Oncol Rep. 2021 May 25;37:100795. doi: 10.1016/j.gore.2021.100795.
    • A rectovaginal septum mass in a BRCA1 positive patient years after risk reducing surgery: A case report.
    • Blankenship L, Lyons YA, Dao Campi H, Valente PT, Barnes L, Kost ER.
    • Gynecol Oncol Rep. 2021 May 5;36:100772. doi: 10.1016/j.gore.2021.100772.
    • Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers.
    • Cowan R, Nobre SP, Pradhan N, Yasukawa M, Zhou QC, Iasonos A, Soslow RA, Arnold AG, Trottier M, Catchings A, Roche KL, Gardner G, Robson M, Abu Rustum NR, Aghajanian C, Cadoo K.
    • Gynecol Oncol. 2021 Mar 9:S0090-8258(21)00142-6. doi: 10.1016/j.ygyno.2021.02.006. Epub ahead of print.
    • Specialist oncological surgery for removal of the ovaries and fallopian tubes in BRCA1 and BRCA2 pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels.
    • Crosbie EJ, Flaum N, Harkness EF, Clayton RD, Holland C, Martin-Hirsch P, Wood N, Keating P, Woodward ER, Lalloo F, Donnai P, Edmondson RJ, Evans DG.
    • Int J Cancer. 2021 Mar 1;148(5):1155-1163. doi: 10.1002/ijc.33378. Epub 2020 Nov 11.
    • Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study.
    • Boerner T, Walch HS, Nguyen B, Iasonos A, Zhou QC, Schultz N, Chui MH, Grisham RN, Tew WP, O'Cearbhaill RE, Aghajanian C, Zivanovic O, Abu-Rustum NR, Gardner GJ, Sonoda Y, Chi DS, Long Roche K.
    • Gynecol Oncol. 2021 Mar;160(3):696-703. doi: 10.1016/j.ygyno.2020.12.022. Epub 2020 Dec 30.
    • Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study.
    • Grandi G, Sammarini M, Cortesi L, Toss A, Botticelli L, Varliero F, Sighinolfi G, Barbieri E, Facchinetti F.
    • Menopause. 2021 Feb 1. doi: 10.1097/GME.0000000000001737. Epub ahead of print.
    • Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
    • Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Goggins M, Hutton ML; CGC, Karlan BY, Khan S, Klein C, Kohlmann W; CGC, Kurian AW, Laronga C, Litton JK, Mak JS; LCGC, Menendez CS, Merajver SD, Norquist BS, Offit K, Pederson HJ, Reiser G; CGC, Senter-Jamieson L; CGC, Shannon KM, Shatsky R, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Yurgelun MB, Darlow SD, Dwyer MA.
    • J Natl Compr Canc Netw. 2021 Jan 6;19(1):77-102. doi: 10.6004/jnccn.2021.0001.
    • Prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers: what is going on in a region of northern Italy?
    • Grandi G, Perrone AM, Perrone A, Mandato VD, Comerci G, Sammarini M, Merisio C, Amadori A, Stefanetti M, Martinello R, Facchinetti F, De Iaco P; Brca Emilia-Romagna Gyneco-Oncological (BERGO) Collaborative Group.
    • Maturitas. 2021 Jan;143:59-64. doi: 10.1016/j.maturitas.2020.08.011. Epub 2020 Aug 31.
    • Value of adjuvant chemotherapy and informed microscopic examination for occult gynecologic cancer detected upon risk-reducing salpingo-oophorectomy after chemotherapy for BRCA1/2-associated breast cancer: a case report.
    • Kuji S, Kondo H, Ohara T, Deura I, Tozawa-Ono A, Migita O, Kawamoto H, Tsugawa K, Chosokabe M, Koike J, Maeda I, Suzuki N.
    • Jpn J Clin Oncol. 2020 Dec 30:hyaa239. doi: 10.1093/jjco/hyaa239. Epub ahead of print.
    • Radiologic-Histopathologic Correlation of Transvaginal US and Risk-reducing Salpingo-oophorectomy for Women at High Risk for Tubo-ovarian Carcinoma.
    • Sakala MD, Curci NE, Masch WR, Mendiratta-Lala M, Stein EB, Wasnik AP, Sciallis AP, Uppal S, Pearlman MD, Maturen KE.
    • Radiol Imaging Cancer. 2020 Nov 13;2(6):e190086. doi: 10.1148/rycan.2020190086.
    • Retrospective evaluation of risk-reducing salpingo-oophorectomy for BRCA1/2 pathogenic variant carriers among a cohort study in a single institution.
    • Kobayashi Y, Hirasawa A, Chiyoda T, Ueki A, Masuda K, Misu K, Kawaida M, Hayashi S, Kataoka F, Banno K, Kosaki K, Aoki D.
    • Jpn J Clin Oncol. 2020 Oct 10:hyaa173. doi: 10.1093/jjco/hyaa173. Epub ahead of print.
    • Pathology of Hereditary Breast and Ovarian Cancer.
    • Hodgson A, Turashvili G.
    • Front Oncol. 2020 Sep 29;10:531790. doi: 10.3389/fonc.2020.531790.
    • Short- and long-term outcomes for single-port risk-reducing salpingo-oophorectomy with and without hysterectomy for women at risk for gynecologic cancer.
    • Carr CE, Chambers L, Jernigan AM, Freeman L, Escobar PF, Michener CM.
    • Int J Gynecol Cancer. 2020 Sep 18:ijgc-2020-001405. doi: 10.1136/ijgc-2020-001405. Epub ahead of print.
    • Morphological and molecular heterogeneity of epithelial ovarian cancer: Therapeutic implications.
    • Romero I, Leskelä S, Mies BP, Velasco AP, Palacios J.
    • EJC Suppl. 2020 Aug 22;15:1-15. doi: 10.1016/j.ejcsup.2020.02.001.
    • Cytologic studies of in vivo fallopian tube specimens in patients undergoing salpingo-oophorectomy.
    • Pramanik S, Yang E, Wu W.
    • Cytojournal. 2020 Aug 10;17:19. doi: 10.25259/CytoJournal_7_2020.
    • Prophylactic Bilateral Salpingo-oophorectomy in BRCA2 Mutation with Incidental Finding of Serous Tubal Intraepithelial Carcinoma (STIC) and Subsequent Diagnosis of Primary Peritoneal Carcinoma (PPC): A Case Report and Review of Current Literature.
    • Palaiologos K, Ellaboudy A, Abdullah M, Karan S, Saha A.
    • Cureus. 2020 Jul 20;12(7):e9301. doi: 10.7759/cureus.9301.
    • The prevalence of occult ovarian cancer in the series of 155 consequently operated high risk asymptomatic patients - Slovenian population based study.
    • Gornjec A, Merlo S, Novakovic S, Stegel V, Gazic B, Perhavec A, Blatnik A, Krajc M.
    • Radiol Oncol. 2020 May 28;54(2):180-186. doi: 10.2478/raon-2020-0020.
    • Long-term outcomes following a diagnosis of ovarian cancer at the time of preventive oophorectomy among BRCA1 and BRCA2 mutation carriers.
    • Kotsopoulos J, Karlan B, Gronwald J, Hall E, Moller P, Tung N, Zakalik D, Foulkes WD, Rosen B, Neuhausen SL, Sun P, Lubinksi J, Narod SA.
    • Int J Gynecol Cancer. 2020 Apr 30. pii: ijgc-2019-001141. doi: 10.1136/ijgc-2019-001141. [Epub ahead of print]
    • Primary fallopian tube carcinoma (PFTC) in a BRIP-1 mutation carrier: the first case report.
    • Grandi G, Caroli M, Alboni C, Cortesi L, Toss A, Barbieri E, Botticelli L, Facchinetti F.
    • Fam Cancer. 2020 Apr 24. doi: 10.1007/s10689-020-00179-0. [Epub ahead of print]
    • Case report
    • Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience.
    • Rush SK, Swisher EM, Garcia RL, Pennington KP, Agnew KJ, Kilgore MR, Norquist BM.
    • Gynecol Oncol. 2020 Mar 18. pii: S0090-8258(20)30101-3. doi: 10.1016/j.ygyno.2020.02.006. [Epub ahead of print]
    • Occult Tubal Carcinoma After Risk-Reducing Salpingo-oophorectomy: A Systematic Review.
    • Piedimonte S, Frank C, Laprise C, Quaiattini A, Gotlieb WH.
    • Obstet Gynecol. 2020 Mar;135(3):498-508. doi: 10.1097/AOG.0000000000003702.
    • Review

    Editorial:

    Unanswered Questions in High-Risk Women Undergoing Risk-Reducing Salpingo-oophorectomy.

    Press: Cancer Threat Persists After Risk-Reducing Surgery — Occult tumors, recurrence, new cancers after prophylactic salpingo-oophorectomy. (Medpage Today)

    • Serous Tubal Intraepithelial Carcinoma: A Concise Review for the Practicing Pathologist and Clinician.
    • Bachert SE, McDowell A Jr, Piecoro D, Baldwin Branch L.
    • Diagnostics (Basel). 2020 Feb 13;10(2). pii: E102. doi: 10.3390/diagnostics10020102.
    • Incidental Serous Tubal Intraepithelial Carcinoma that Developed into Primary Peritoneal Serous Carcinoma in a Patient without BRCA Mutation.
    • Chong GO, Park JY, Lee HJ.
    • Am J Case Rep. 2020 Feb 8;21:e921146. doi: 10.12659/AJCR.921146.
    • The incidence of occult ovarian neoplasia and cancer in BRCA1/2 mutation carriers after the bilateral prophylactic salpingo-oophorectomy (PBSO): A single-center prospective study.
    • Rudaitis V, Mikliusas V, Januska G, Jukna P, Mickys U, Janavicius R.
    • Eur J Obstet Gynecol Reprod Biol. 2020 Jan 30;247:26-31. doi: 10.1016/j.ejogrb.2020.01.040. [Epub ahead of print]
    • Risk-Reducing Bilateral Salpingo-Oophorectomy: Assessing the Incidence of Occult Ovarian Cancer and Surgeon Adherence to Recommended Practices.
    • Newcomb LK, Toal CT, Rindos NB, Wang L, Mansuria SM.
    • J Minim Invasive Gynecol. 2020 Jan 9. pii: S1553-4650(20)30037-6. doi: 10.1016/j.jmig.2020.01.004. [Epub ahead of print]
    • Cytological sampling of fallopian tubes using a hysteroscopic catheter: A multi-center study.
    • Powell CB, Littell RD, Landen CN Jr, Pramanik S, Hamilton IC, Suh-Burgmann EJ.
    • Gynecol Oncol. 2020 Jan 7. pii: S0090-8258(19)31847-5. doi: 10.1016/j.ygyno.2019.12.026. [Epub ahead of print]
    • The fallopian tube as origin of ovarian cancer: Change of diagnostic and preventive strategies.
    • Kyo S, Ishikawa N, Nakamura K, Nakayama K.
    • Cancer Med. 2019 Nov 25. doi: 10.1002/cam4.2725. [Epub ahead of print]
    • A comparison of ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy.
    • Gronwald J, Lubinski J, Huzarski T, Cybulski C, Menkiszak J, Siołek M, Stawicka M, Sun P, Kim S, Kotsopoulos J, Narod SA.
    • Gynecol Oncol. 2019 Sep 6. pii: S0090-8258(19)31486-6. doi: 10.1016/j.ygyno.2019.08.034. [Epub ahead of print]
    • Pathological findings following risk-reducing salpingo-oophorectomy in BRCA mutation carriers: A systematic review and meta-analysis.
    • Cheng A, Li L, Wu M, Lang J.
    • Eur J Surg Oncol. 2019 Sep 5. pii: S0748-7983(19)30662-6. doi: 10.1016/j.ejso.2019.09.002. [Epub ahead of print]
    • Health Care Provider Adherence to Surgical Guidelines for Risk-Reducing Salpingo-Oophorectomy.
    • Wilhite AM, Oestreich MC, Olson M, Bedell SM, Westenberg D, Bangdiwala A, Ikramuddin S, Sanchez-Avila M, Madoff RD, Khalifa MA, Erickson BK.
    • Obstet Gynecol. 2019 Sep;134(3):520-526. doi: 10.1097/AOG.0000000000003421.
    • Management of ovarian cancer risk in women with BRCA1/2 pathogenic variants.
    • Walker M, Jacobson M, Sobel M.
    • CMAJ. 2019 Aug 12;191(32):E886-E893. doi: 10.1503/cmaj.190281.
    • Peritoneal involvement by salpingoliths clinical significance and cytological challenges of interpretation.
    • El Hussein S, Guerrero D, Khader SN.
    • Diagn Cytopathol. 2019 Aug 7. doi: 10.1002/dc.24299. [Epub ahead of print]
    • Case report
    • Contemporary management of adnexa at the time of benign hysterectomy: a review of the literature.
    • Tamhane N, Imudia AN, Mikhail E.
    • J Obstet Gynaecol. 2019 Jul 13:1-7. doi: 10.1080/01443615.2019.1581747. [Epub ahead of print]
    • Review
    • Ovarian remnant syndrome in an aromatase inhibitor-treated patient with BRCA2 mutation following bilateral oophorectomy.
    • Wei M, Maurer KA, Henry NL.
    • Breast J. 2019 Jul 4. doi: 10.1111/tbj.13454. [Epub ahead of print]
    • Case report
    • Challenges in Managing Patients with Hereditary Cancer at Gynecological Services.
    • Ueda M, Tsubamoto H, Kashima-Morii M, Torii Y, Kamihigashi M, Wakimoto Y, Nakagomi N, Hashimoto-Tamaoki T, Sawai H, Shibahara H.
    • Obstet Gynecol Int. 2019 May 27;2019:4365754. doi: 10.1155/2019/4365754. eCollection 2019.
    • Development of Peritoneal Carcinoma in women diagnosed with Serous Tubal Intraepithelial Carcinoma (STIC) following Risk-Reducing Salpingo-Oophorectomy (RRSO).
    • Stanciu PI, Ind TEJ, Barton DPJ, Butler JB, Vroobel KM, Attygalle AD, Nobbenhuis MAE.
    • J Ovarian Res. 2019 May 25;12(1):50. doi: 10.1186/s13048-019-0525-1.
    • Opportunistic Salpingectomy at the Time of Urogynecologic Surgery: Why, in Whom, and How?
    • Catanzarite T, Eskander RN.
    • Female Pelvic Med Reconstr Surg. 2019 May 22. doi: 10.1097/SPV.0000000000000741. [Epub ahead of print]
    • Review
    • Retrospective study of a 16 year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up.
    • Blok F, Dasgupta S, Dinjens WNM, Roes EM, van Beekhuizen HJ, Ewing-Graham PC.
    • Gynecol Oncol. 2019 May;153(2):326-334. doi: 10.1016/j.ygyno.2019.03.003. Epub 2019 Mar 18.
    • An Alternate Diagnostic Algorithm for the Diagnosis of Intraepithelial Fallopian Tube Lesions.
    • Perrone ME, Reder NP, Agoff SN, Garcia RL, Agnew KJ, Norquist BM, Pennington KP, Swisher EM, Kilgore MR.
    • Int J Gynecol Pathol. 2019 Apr 24. doi: 10.1097/PGP.0000000000000604. [Epub ahead of print]
    • Surgery to Reduce Ovarian Cancer Risk — One Step or Two?
    • Harrison P
    • Medscape. Medscape Oncology. 2019 Mar 25.
    • Early-onset primary peritoneal carcinoma from atypical cells after risk-reducing salpingo-oophorectomy for BRCA2 mutation carrier: a case report.
    • Shimizu H, Ishikawa T, Iitsuka C, Homma M, Takimoto M, Sekizawa A.
    • Int Cancer Conf J. 2017 Mar 21;6(3):104-108. doi: 10.1007/s13691-017-0287-9. eCollection 2017 Jul.
    • Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy.
    • Menkiszak J, Chudecka-Głaz A, Cymbaluk-Płoska A, Celewicz A, Kojs Z, Szajda M, Świniarska M, Bedner R, Jurczak A, Celewicz M, Cieszyńska M, Lubiński J, Gronwald J.
    • Hered Cancer Clin Pract. 2019 Mar 14;17:10. doi: 10.1186/s13053-019-0109-5. eCollection 2019.
    • High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints.
    • Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C.
    • Int J Mol Sci. 2019 Feb 22;20(4). pii: E952. doi: 10.3390/ijms20040952.
    • Concurrent isolated retroperitoneal HGSC and STIC defined by somatic mutation analysis: a case report.
    • Suda K, Nakaoka H, Hata C, Yahata N, Isobe M, Kameyama H, Wakai T, Motoyama T, Inoue I, Yoshihara K, Enomoto T.
    • Diagn Pathol. 2019 Feb 11;14(1):17. doi: 10.1186/s13000-019-0795-3.
    • Evaluation of screening and risk-reducing surgery for women followed in a high-risk breast/ovarian cancer clinic: it is all about the tubes in BRCA mutation carriers.
    • Stewart ME, Knisely AT, Sullivan MW, Ring KL, Modesitt SC.
    • Gynecol Oncol Rep. 2019 Feb 1;28:18-22. doi: 10.1016/j.gore.2019.01.010. eCollection 2019 May.
    • The fallopian tube, "precursor escape" and narrowing the knowledge gap to the origins of high-grade serous carcinoma.
    • Soong TR, Howitt BE, Horowitz N, Nucci MR, Crum CP.
    • Gynecol Oncol. 2019 Feb;152(2):426-433. doi: 10.1016/j.ygyno.2018.11.033. Epub 2018 Nov 30.
    • Review
    • Population Frequency of Serous Tubal Intraepithelial Carcinoma (STIC) in Clinical Practice Using SEE-Fim Protocol.
    • Samimi G, Trabert B, Geczik AM, Duggan MA, Sherman ME.
    • JNCI Cancer Spectr. 2018 Dec 14;2(4):pky061. doi: 10.1093/jncics/pky061. eCollection 2018 Oct.
    • Back to the Future? The Fallopian Tube, Precursor Escape and a Dualistic Model of High-Grade Serous Carcinogenesis.
    • Soong TR, Kolin DL, Teschan NJ, Crum CP.
    • Cancers (Basel). 2018 Nov 28;10(12). pii: E468. doi: 10.3390/cancers10120468.
    • An Unusual Adenomatoid Tumor of Fimbria with Pronounced Psammoma Bodies in a BRCA Positive Patient as a Pitfall for Carcinoma on Frozen Section.
    • Lee CM, Moh M, Sullivan PS, Moatamed NA.
    • Case Rep Pathol. 2018 Nov 21;2018:8148147. doi: 10.1155/2018/8148147. eCollection 2018.
    • Cell Origins of High-Grade Serous Ovarian Cancer.
    • Kim J, Park EY, Kim O, Schilder JM, Coffey DM, Cho CH, Bast RC Jr.
    • Cancers (Basel). 2018 Nov 12;10(11). pii: E433. doi: 10.3390/cancers10110433.
    • Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study.
    • Visvanathan K, Shaw P, May BJ, Bahadirli-Talbott A, Kaushiva A, Risch H, Narod S, Wang TL, Parkash V, Vang R, Levine DA, Soslow R, Kurman R, Shih IM.
    • Cancer Prev Res (Phila). 2018 Nov;11(11):697-706. doi: 10.1158/1940-6207.CAPR-18-0009. Epub 2018 Sep 19.
    • No. 366-Gynaecologic Management of Hereditary Breast and Ovarian Cancer.
    • Jacobson M, Bernardini M, Sobel ML, Kim RH, McCuaig J, Allen L.
    • J Obstet Gynaecol Can. 2018 Nov;40(11):1497-1510. doi: 10.1016/j.jogc.2018.05.046.
    • Guidelines

    [Article in French]:

    No 366 - Prise en charge gynécologique du cancer du sein et de l'ovaire héréditaire.

    • Subsequent breast and high grade serous carcinomas after risk-reducing salpingo-oophorectomy in BRCA mutation carriers and patients with history of breast cancer.
    • Straub MM, Podoll MB, David SN, Wiesner GL, Desouki MM.
    • Ann Diagn Pathol. 2018 Oct;36:28-30. doi: 10.1016/j.anndiagpath.2018.06.003. Epub 2018 Jun 27.
    • Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish study.
    • Minig L, Cabrera S, Oliver R, Couso A, Rubio MJ, Iacoponi S, Martin-Salamanca MB, Carballo-Rastrilla S, Cádenas-Rebollo JM, García-Garcia A, Gil-Ibáñez B, Juan-Fita MJ, Patrono MG.
    • Clin Transl Oncol. 2018 Oct;20(10):1337-1344. doi: 10.1007/s12094-018-1865-9. Epub 2018 Apr 5.
    • Evaluation of Microscopic Changes in Fallopian Tubes of BRCA Mutation Carriers by Morphometric Analysis of Histologic Slides: A Preliminary Pilot Study.
    • Amit A, Sabo E, Zohar Y, Trugman E, Pranovich I, Reiss A, Matanes E, Klorin G.
    • Int J Gynecol Pathol. 2018 Sep;37(5):460-467. doi: 10.1097/PGP.0000000000000440.
    • Outcome and Prognostic Impact of Surgical Staging in Serous Tubal Intraepithelial Carcinoma: A Cohort Study and Systematic Review.
    • Van der Hoeven NMA, Van Wijk K, Bonfrer SE, Beltman JJ, Louwe LA, De Kroon CD, Van Asperen CJ, Gaarenstroom KN.
    • Clin Oncol (R Coll Radiol). 2018 Aug;30(8):463-471. doi: 10.1016/j.clon.2018.03.036. Epub 2018 Apr 22.
    • Risk reduction surgery (RRS) for tubo-ovarian cancer in an Irish gynaecological practice: an analysis of indications and outcomes.
    • Thompson C, McCormick C, Kamran W, O'Riain C, Norris L, Gallagher D, Gleeson N.
    • Ir J Med Sci. 2018 Aug;187(3):789-794. doi: 10.1007/s11845-017-1717-6. Epub 2018 Jan 3.
    • Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations.
    • Nebgen DR, Hurteau J, Holman LL, Bradford A, Munsell MF, Soletsky BR, Sun CC, Chisholm GB, Lu KH.
    • Gynecol Oncol. 2018 Jul;150(1):79-84. doi: 10.1016/j.ygyno.2018.04.564. Epub 2018 May 4.
    • Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation.
    • Kotsopoulos J, Gronwald J, Karlan B, Rosen B, Huzarski T, Moller P, Lynch HT, Singer CF, Senter L, Neuhausen SL, Tung N, Eisen A, Foulkes WD, Ainsworth P, Sun P, Lubinski J, Narod SA; Hereditary Ovarian Cancer Clinical Study Group.
    • Gynecol Oncol. 2018 Jul;150(1):85-91. doi: 10.1016/j.ygyno.2018.05.011. Epub 2018 May 21.
    • Intra-operative evaluation of prophylactic hysterectomy and salpingo-oophorectomy specimens in hereditary gynaecological cancer syndromes.
    • Wong S, Ratner E, Buza N.
    • Histopathology. 2018 Jul;73(1):109-123. doi: 10.1111/his.13503. Epub 2018 Apr 16.
    • The clinical impact of serous tubal intraepithelial carcinoma on outcomes of patients with high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum.
    • Toptas T, Pestereli E, Simsek T, Bozkurt S, Erdogan G, Karaveli S.
    • J Cancer Res Ther. 2018 Apr-Jun;14(3):587-592. doi: 10.4103/0973-1482.172130.
    • Observations on the origin of ovarian cortical inclusion cysts in women undergoing risk-reducing salpingo-oophorectomy.
    • Park KJ, Patel P, Linkov I, Jotwani A, Kauff N, Pike MC.
    • Histopathology. 2018 Apr;72(5):766-776. doi: 10.1111/his.13444. Epub 2018 Jan 29.
    • Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan.
    • Arai M, Yokoyama S, Watanabe C, Yoshida R, Kita M, Okawa M, Sakurai A, Sekine M, Yotsumoto J, Nomura H, Akama Y, Inuzuka M, Nomizu T, Enomoto T, Nakamura S.
    • J Hum Genet. 2018 Apr;63(4):447-457. doi: 10.1038/s10038-017-0355-1. Epub 2017 Nov 8.
    • Peritoneal carcinomatosis after risk-reducing surgery in BRCA1/2 mutation carriers.
    • Harmsen MG, Piek JMJ, Bulten J, Casey MJ, Rebbeck TR, Mourits MJ, Greene MH, Slangen BFM, van Beurden M, Massuger LFAG, Hoogerbrugge N, de Hullu JA.
    • Cancer. 2018 Mar 1;124(5):952-959. doi: 10.1002/cncr.31211. Epub 2018 Jan 9.

    Editorial:

    Who is at risk after risk reduction?

    • Prophylactic mastectomy for BRCA mutation carriers after ovarian cancer treatment: is it beneficial?
    • Kotsopoulos J, Narod SA.
    • Expert Rev Anticancer Ther. 2018 Mar;18(3):199-200. doi: 10.1080/14737140.2018.1424547. Epub 2018 Jan 8.
    • Processing of fallopian tube, ovary, and endometrial surgical pathology specimens: A survey of U.S. laboratory practices.
    • Samimi G, Trabert B, Duggan MA, Robinson JL, Coa KI, Waibel E, Garcia E, Minasian LM, Sherman ME.
    • Gynecol Oncol. 2018 Mar;148(3):515-520. doi: 10.1016/j.ygyno.2018.01.016.
    • Synchronous Bilateral Tubal Serous Carcinomas in a Patient With Exon 13 Duplication and Loss of Function of BRCA1.
    • Gurda GT, Serdy KM, Yatsenko SA, Rajkovic A, Carter NJ, Ahmed R, Olawaiye AB, Bhargava R, Elishaev E.
    • Int J Gynecol Pathol. 2018 Mar;37(2):117-122. doi: 10.1097/PGP.0000000000000392.
    • Expression of βV-Tubulin in Secretory Cells of the Fallopian Tube Epithelium Marks Cellular Atypia.
    • Mathew D, Wang Y, Van Arsdale A, Horwitz SB, McDaid H.
    • Int J Gynecol Cancer. 2018 Feb;28(2):363-370. doi: 10.1097/IGC.0000000000001160.
    • Surgical Findings and Outcomes in Premenopausal Breast Cancer Patients Undergoing Oophorectomy: A Multicenter Review From the Society of Gynecologic Surgeons Fellows Pelvic Research Network.
    • Harvey LFB, Abramson VG, Alvarez J, DeStephano C, Hur HC, Lee K, Mattingly P, Park B, Piszczek C, Seifi F, Stuparich M, Yunker A.
    • J Minim Invasive Gynecol. 2018 Jan;25(1):111-115. doi: 10.1016/j.jmig.2017.08.643. Epub 2017 Aug 15.
    • A salpingeal carcinoma revealed after prophylactic salpingoophorectomy in an asymptomatic BRCA1 carrier with breast malignancy.
    • Giannos A, Stavrou S, Douskos A, Drakakis P, Loutradis D.
    • Int J Surg Case Rep. 2018;52:107-110. doi: 10.1016/j.ijscr.2018.10.014. Epub 2018 Oct 12.
    • [Does ovarian cancer start in the fallopian tubes? Possible implications for preventive adnexal removal].
    • Steenbeek MP, Bulten J, Hoogerbrugge N, Massuger LFAG, Pijnenborg JMA, de Hullu JA.
    • Ned Tijdschr Geneeskd. 2018;162(0):D2337.
    • Case report, [Article in Dutch]
    • "Best practices in risk reducing bilateral salpingo-oophorectomy: the influence of surgical specialty".
    • Malacarne DR, Boyd LR, Long Y, Blank SV.
    • World J Surg Oncol. 2017 Dec 11;15(1):218. doi: 10.1186/s12957-017-1282-5.
    • Cells of origin of ovarian cancer: ovarian surface epithelium or fallopian tube?
    • Klotz DM, Wimberger P.
    • Arch Gynecol Obstet. 2017 Dec;296(6):1055-1062. doi: 10.1007/s00404-017-4529-z. Epub 2017 Sep 23.
    • Review
    • Management of Preinvasive Lesions.
    • Patrono MG, Corzo C, Iniesta M, Ramirez PT.
    • Clin Obstet Gynecol. 2017 Dec;60(4):771-779. doi: 10.1097/GRF.0000000000000316.
    • Review
    • VUS Reclassified to "Suspected Deleterious": When Genetic Counseling Updates Become Life-Saving.
    • [No author given]
    • My Gene Counsel. 2017 Nov 30.
    • Traceback: leveraging archived biospecimens to identify mutation carriers.
    • Samimi G, Sherman ME.
    • Oncotarget. 2017 Oct 11;8(53):90628-90629. doi: 10.18632/oncotarget.21742. eCollection 2017 Oct 31.
    • High grade serous ovarian carcinomas originate in the fallopian tube.
    • Labidi-Galy SI, Papp E, Hallberg D, Niknafs N, Adleff V, Noe M, Bhattacharya R, Novak M, Jones S, Phallen J, Hruban CA, Hirsch MS, Lin DI, Schwartz L, Maire CL, Tille JC, Bowden M, Ayhan A, Wood LD, Scharpf RB, Kurman R, Wang TL, Shih IM, Karchin R, Drapkin R, Velculescu VE.
    • Nat Commun. 2017 Oct 23;8(1):1093. doi: 10.1038/s41467-017-00962-1.
    • Re: A paradigm shift in the origin of ovarian cancer: the ovary is no longer to blame: Is the ovary to blame for tubal carcinoma?
    • Fathalla MF.
    • BJOG. 2017 Oct;124(11):1796-1797. doi: 10.1111/1471-0528.14769.

    A paradigm shift in the origin of ovarian cancer: the ovary is no longer to blame.

    • Sequential molecular changes and dynamic oxidative stress in high-grade serous ovarian carcinogenesis.
    • Kobayashi H, Ogawa K, Kawahara N, Iwai K, Niiro E, Morioka S, Yamada Y.
    • Free Radic Res. 2017 Oct;51(9-10):755-764. doi: 10.1080/10715762.2017.1383605. Epub 2017 Oct 11.
    • Risk-reducing Salpingo-Oophorectomy in Women at Higher Risk of Ovarian and Breast Cancer: A Single Institution Prospective Series.
    • Ricciardi E, Tomao F, Aletti G, Bazzurini L, Bocciolone L, Boveri S, Landoni F, Lapresa MT, Maruccio M, Parma G, Peccatori F, Petrella MC, Zanagnolo V, Colombo N, Maggioni A.
    • Anticancer Res. 2017 Sep;37(9):5241-5248.
    • LEF1 is preferentially expressed in the tubal-peritoneal junctions and is a reliable marker of tubal intraepithelial lesions.
    • Schmoeckel E, Odai-Afotey AA, Schleißheimer M, Rottmann M, Flesken-Nikitin A, Ellenson LH, Kirchner T, Mayr D, Nikitin AY.
    • Mod Pathol. 2017 Sep;30(9):1241-1250. doi: 10.1038/modpathol.2017.53. Epub 2017 Jun 30.
    • The Role of Routine Peritoneal and Omental Biopsies at Risk-Reducing Salpingo-Oophorectomy.
    • Miller H, Pipkin LS, Tung C, Hall TR, Masand RP, Anderson ML.
    • J Minim Invasive Gynecol. 2017 Jul - Aug;24(5):772-776. doi: 10.1016/j.jmig.2017.03.001. Epub 2017 Mar 8.
    • Assessing the risk of occult cancer and 30-day morbidity in women undergoing risk-reducing surgery: a prospective experience.
    • Bogani G, Tagliabue E, Signorelli M, Chiappa V, Carcangiu ML, Paolini B, Casarin J, Scaffa C, Gennaro M, Martinelli F, Borghi C, Ditto A, Lorusso D, Raspagliesi F.
    • J Minim Invasive Gynecol. 2017 Jul - Aug;24(5):837-842. doi: 10.1016/j.jmig.2017.04.017. Epub 2017 May 4.
    • Frequency of "incidental" serous tubal intraepithelial carcinoma (STIC) in women without a history of or genetic risk factor for high-grade serous carcinoma: A six-year study.
    • Meserve EEK, Mirkovic J, Conner JR, Yang E, Muto MG, Horowitz N, Strickland KC, Howitt BE, Crum CP.
    • Gynecol Oncol. 2017 Jul;146(1):69-73. doi: 10.1016/j.ygyno.2017.04.015. Epub 2017 May 4.
    • Frequency of “incidental” serous tubal intraepithelial carcinoma (STIC) in women without a history of or genetic risk factor for high-grade serous carcinoma: A six-year study.
    • Meserve EEK, Mirkovic J, Conner JR, Yang E, Muto MG, Horowitz N, Strickland KC, Howitt BE, Crum CP.
    • Gynecol Oncol. 2017 May 4. pii: S0090-8258(17)30796-5. doi: 10.1016/j.ygyno.2017.04.015. [Epub ahead of print]
    • Is There a Role for Ovarian Cancer Screening in High-Risk Women?
    • Berchuck A, Havrilesky LJ, Kauff ND.
    • J Clin Oncol. 2017 May 1;35(13):1384-1386. doi: 10.1200/JCO.2016.72.0045. Epub 2017 Mar 6.

    Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study.

    • Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study.
    • Rosenthal AN, Fraser LS, Philpott S, Manchanda R, Burnell M, Badman P, Hadwin R, Rizzuto I, Benjamin E, Singh N, Evans DG, Eccles DM, Ryan A, Liston R, Dawnay A, Ford J, Gunu R, Mackay J, Skates SJ, Menon U, Jacobs IJ; United Kingdom Familial Ovarian Cancer Screening Study collaborators.
    • J Clin Oncol. 2017 May 1;35(13):1411-1420. doi: 10.1200/JCO.2016.69.9330. Epub 2017 Feb 27.

    Editorial:

    Is There a Role for Ovarian Cancer Screening in High-Risk Women?

    • A paradigm shift in the origin of ovarian cancer: the ovary is no longer to blame.
    • Meyn A, Lim B.
    • BJOG. 2017 May;124(6):859. doi: 10.1111/1471-0528.14609.

    Letter:

    Re: A paradigm shift in the origin of ovarian cancer: the ovary is no longer to blame: Is the ovary to blame for tubal carcinoma?

    • The Impact of an Expanded Genetic Testing Program and Selective Oophorectomy on the Incidence of Ovarian Cancer in West Pomerania.
    • Menkiszak J, Sopik V, Chudecka-Głaz A, Domagała W, Urasińska E, Symonowicz H, Majdanik E, Waloszczyk P, Sycz K, Świniarska M, Huzarski T, Cybulski C, Debniak T, Oszurek O, Lubinski J, Narod SA, Gronwald J.
    • Clin Genet. 2017 Feb;91(2):322-327. doi: 10.1111/cge.12865. Epub 2016 Oct 19.
    • [Clinical Management of HBOC in Our Hospital].
    • Nomura H, Takeshima N.
    • Gan To Kagaku Ryoho. 2017 Feb;44(2):116-120.
    • [Article in Japanese]
    • Role of Fallopian Tubes in the Development of Ovarian Cancer.
    • Corzo C, Iniesta MD, Patrono MG, Lu KH, Ramirez PT.
    • J Minim Invasive Gynecol. 2017 Feb;24(2):230-234. doi: 10.1016/j.jmig.2016.12.007. Epub 2016 Dec 19.
    • Review
    • Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers.
    • Lee YJ, Lee SW, Kim KR, Jung KH, Lee JW, Kim YM.
    • J Gynecol Oncol. 2017 Jan;28(1):e3. doi: 10.3802/jgo.2017.28.e3. Epub 2016 Aug 8.
    • HE4 Serum Levels in Patients with BRCA1 Gene Mutation Undergoing Prophylactic Surgery as well as in Other Benign and Malignant Gynecological Diseases.
    • Chudecka-Głaz A, Cymbaluk-Płoska A, Strojna A, Menkiszak J.
    • Dis Markers. 2017;2017:9792756. doi: 10.1155/2017/9792756. Epub 2017 Jan 15.
    • Serous tubal intraepithelial carcinoma (STIC) - clinical impact and management.
    • Weinberger V, Bednarikova M, Cibula D, Zikan M.
    • Expert Rev Anticancer Ther. 2016 Dec;16(12):1311-1321. Epub 2016 Oct 22.
    • Review
    • STIC-ing with what we know.
    • Chen LM.
    • Gynecol Oncol. 2016 Nov;143(2):227-228. doi: 10.1016/j.ygyno.2016.10.007.
    • Editorial
    • Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers.
    • Zakhour M, Danovitch Y, Lester J, Rimel BJ, Walsh CS, Li AJ, Karlan BY, Cass I.
    • Gynecol Oncol. 2016 Nov;143(2):231-235. doi: 10.1016/j.ygyno.2016.08.336. Epub 2016 Sep 9.
    • Incidence and Characteristics of Unsuspected Neoplasia Discovered in High-Risk Women Undergoing Risk Reductive Bilateral Salpingooophorectomy.
    • Poon C, Hyde S, Grant P, Newman M, Ireland Jenkin K.
    • Int J Gynecol Cancer. 2016 Oct;26(8):1415-20. doi: 10.1097/IGC.0000000000000791.
    • [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
    • Škapa P, Dundr P.
    • Cesk Patol. 2016 Fall;52(4):199-204.
    • Incidental Serous Tubal Intraepithelial Carcinoma and Non-Neoplastic Conditions of the Fallopian Tubes in Grossly Normal Adnexa: A Clinicopathologic Study of 388 Completely Embedded Cases.
    • Seidman JD, Krishnan J, Yemelyanova A, Vang R.
    • Int J Gynecol Pathol. 2016 Sep;35(5):423-429.
    • Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies.
    • Hellner K, Miranda F, Fotso Chedom D, Herrero-Gonzalez S, Hayden DM, Tearle R, Artibani M, KaramiNejadRanjbar M, Williams R, Gaitskell K, Elorbany S, Xu R, Laios A, Buiga P, Ahmed K, Dhar S, Zhang RY, Campo L, Myers KA, Lozano M, Ruiz-Miró M, Gatius S, Mota A, Moreno-Bueno G, Matias-Guiu X, Benítez J, Witty L, McVean G, Leedham S, Tomlinson I, Drmanac R, Cazier JB, Klein R, Dunne K, Bast RC Jr, Kennedy SH, Hassan B, Lise S, Garcia MJ, Peters BA, Yau C, Sauka-Spengler T, Ahmed AA.
    • EBioMedicine. 2016 Aug;10:137-49. doi: 10.1016/j.ebiom.2016.06.048. Epub 2016 Jul 2.
    • Prophylactic Gynecologic Specimens from Hereditary Cancer Carriers.
    • Shaw PA, Clarke BA.
    • Surg Pathol Clin. 2016 Jun;9(2):307-28. doi: 10.1016/j.path.2016.02.002.
    • Review
    • Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers.
    • Menkiszak J, Chudecka-Głaz A, Gronwald J, Cymbaluk-Płoska A, Celewicz A, Świniarska M, Wężowska M, Bedner R, Zielińska D, Tarnowska P, Jakubowicz J, Kojs Z.
    • J Ovarian Res. 2016 Feb 29;9(1):11. doi: 10.1186/s13048-016-0220-4.
    • Clinical and Pathological Characteristics of Incidental Diagnostic Early Occult Malignancy After Risk-Reducing Salpingo-Oophorectomy in BRCA Mutation Carriers.
    • Lavie O, Moskoviz MG, Auslender R, Gemer O, Bitterman A, Younes G, Segev Y.
    • Int J Gynecol Cancer. 2016 Feb;26(2):233-9. doi: 10.1097/IGC.0000000000000624.
    • The lack of clinical value of peritoneal washing cytology in high risk patients undergoing risk-reducing salpingo-oophorectomy: a retrospective study and review.
    • Blok F, Roes EM, van Leenders GJ, van Beekhuizen HJ.
    • BMC Cancer. 2016 Jan 14;16(1):18. doi: 10.1186/s12885-015-2011-5.
    • Serous tubal intraepithelial carcinoma arising from the intrauterine portion of the fallopian tube after bilateral salpingo-oophorectomy.
    • Yoshida H, Shintani D, Imai Y, Fujiwara K.
    • Eur J Gynaecol Oncol. 2016;37(3):404-6.
    • [Case report]
    • Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): A comprehensive review.
    • Patrono MG, Iniesta MD, Malpica A, Lu KH, Fernandez RO, Salvo G, Ramirez PT.
    • Gynecol Oncol. 2015 Dec;139(3):568-572. doi: 10.1016/j.ygyno.2015.09.018. Epub 2015 Sep 25.
    • Review
    • [Early epithelial lesions in prophylactic annexectomies in patients at high risk of ovarian cancer: Report of a series of 93 cases].
    • Selmes G, Ferron G, Filleron T, Querleu D, Mery E.
    • Gynecol Obstet Fertil. 2015 Oct;43(10):659-64. doi: 10.1016/j.gyobfe.2015.07.006.
    • [Article in French]
    • Cancer precursor lesions in the BRCA population at the time of prophylactic salpingo-oophorectomy: Accuracy of assessment and potential surrogate marker for prevention.
    • Lheureux S, Shaw PA, Karakasis K, Oza AM.
    • Gynecol Oncol. 2015 Aug;138(2):235-237. doi: 10.1016/j.ygyno.2015.06.014. Epub 2015 Jun 10.
    • Editorial / Commentary
    • Pathologic findings at risk-reducing surgery.
    • Mourits MJ, de Bock GH, Hollema H.
    • J Clin Oncol. 2015 May 1;33(13):1514. doi: 10.1200/JCO.2014.59.3376. Epub 2015 Mar 2.

    Pathologic Findings at Risk-Reducing Salpingo-Oophorectomy: Primary Results From Gynecologic Oncology Group Trial GOG-0199.

    Letter

    Reply to m.j. Mourits et Al.

    • Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series.
    • Morrison JC, Blanco LZ Jr, Vang R, Ronnett BM.
    • Am J Surg Pathol. 2015 Apr;39(4):442-53. doi: 10.1097/PAS.0000000000000352.
    • Low grade serious carcinoma of the peritoneum in a BRCA1 carrier previously diagnosed with a "low-grade serous tubal intra-epithelial carcinoma" (STIC) on risk reducing surgery.
    • Chay WY, Horlings HM, Tinker AV, Gelmon KA, Gilks CB.
    • Gynecol Oncol Rep. 2015 Mar 28;12:72-4. doi: 10.1016/j.gore.2015.03.007. eCollection 2015.
    • Serous Tubal Intraepithelial Carcinoma Localizes to the Tubal-peritoneal Junction: A Pivotal Clue to the Site of Origin of Extrauterine High-grade Serous Carcinoma (Ovarian Cancer).
    • Seidman JD.
    • Int J Gynecol Pathol. 2015 Mar;34(2):112-20. doi: 10.1097/PGP.0000000000000123.
    • Stopping ovarian cancer screening in BRCA1/2 mutation carriers: Effects on risk management decisions & outcome of risk-reducing salpingo-oophorectomy specimens.
    • van Driel CM, de Bock GH, Arts HJ, Sie AS, Hollema H, Oosterwijk JC, Mourits MJ.
    • Maturitas. 2015 Mar;80(3):318-22. doi: 10.1016/j.maturitas.2014.12.009. Epub 2014 Dec 30.
    • Serous tubal intraepithelial carcinoma: an incidental finding at the time of prophylactic bilateral salpingo-oophorectomy.
    • Vaughan MH, Modesitt SC, Mo Y, Trowbridge ER.
    • Case Rep Obstet Gynecol. 2015;2015:760429. doi: 10.1155/2015/760429. Epub 2015 Feb 23.
    • Morphological and immunohistochemical pattern of tubo-ovarian dysplasia and serous tubal intraepithelial carcinoma.
    • Chene G, Cayre A, Raoelfils I, Lagarde N, Dauplat J, Penault-Llorca F.
    • Eur J Obstet Gynecol Reprod Biol. 2014 Dec;183:89-95. doi: 10.1016/j.ejogrb.2014.10.003. Epub 2014 Oct 14.
    • Occult and subsequent gynecologic cancers following risk-reducing salpingo-oophorectomies (RRSO) in BRCA mutation carriers.
    • Zakhour M, Karlan BY, Walts AE, Gross J, Rimel BJ, Walsh C, Li AJ, Cass I.
    • Gynecologic Oncology. 2014 Nov;135(2):384. 2014 WAGO ABSTRACTS. doi: 10.1016/j.ygyno.2014.07.013.
    • Conference abstract
    • Pathologic Findings at Risk-Reducing Salpingo-Oophorectomy: Primary Results From Gynecologic Oncology Group Trial GOG-0199.
    • Sherman ME, Piedmonte M, Mai PL, Ioffe OB, Ronnett BM, Van Le L, Ivanov I, Bell MC, Blank SV, DiSilvestro P, Hamilton CA, Tewari KS, Wakeley K, Kauff ND, Yamada SD, Rodriguez G, Skates SJ, Alberts DS, Walker JL, Minasian L, Lu K, Greene MH.
    • J Clin Oncol. 2014 Oct 10;32(29):3275-83. doi: 10.1200/JCO.2013.54.1987. Epub 2014 Sep 8.

    Letter, Comment:

    Pathologic findings at risk-reducing surgery.

    Letter, Reply:

    Reply to m.j. Mourits et Al.

    • A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers.
    • Cass I, Walts AE, Barbuto D, Lester J, Karlan B.
    • Gynecol Oncol. 2014 Sep;134(3):492-7. doi: 10.1016/j.ygyno.2014.07.084. Epub 2014 Jul 12.
    • Genomic Aberrations of BRCA1-Mutated Fallopian Tube Carcinomas.
    • Hunter SM, Ryland GL, Moss P; kConFab Investigators, Gorringe KL, Campbell IG.
    • Am J Pathol. 2014 Jun;184(6):1871-6. doi: 10.1016/j.ajpath.2014.02.013. Epub 2014 Apr 13.
    • Early Detection of High-grade Tubal Serous Carcinoma in Women at Low Risk for Hereditary Breast and Ovarian Cancer Syndrome by Systematic Examination of Fallopian Tubes Incidentally Removed During Benign Surgery.
    • Rabban JT, Garg K, Crawford B, Chen LM, Zaloudek CJ.
    • Am J Surg Pathol. 2014 Jun;38(6):729-42. doi: 10.1097/PAS.0000000000000199.
    • Serous tubal intraepithelial carcinoma in a Japanese woman with a deleterious BRCA1 mutation.
    • Ishikawa H, Kiyokawa T, Utsuno E, Matsushita K, Nomura F, Shozu M.
    • Jpn J Clin Oncol. 2014 Jun;44(6):597-601. doi: 10.1093/jjco/hyu035. Epub 2014 Apr 9.
    • Prophylactic bilateral salpingectomy (PBS) to reduce ovarian cancer risk incorporated in standard premenopausal hysterectomy: complications and re-operation rate.
    • Vorwergk J, Radosa MP, Nicolaus K, Baus N, Jimenez Cruz J, Rengsberger M, Gajda M, Diebolder H, Runnebaum IB.
    • J Cancer Res Clin Oncol. 2014 May;140(5):859-65. doi: 10.1007/s00432-014-1622-6. Epub 2014 Feb 27.
    • Occult tubal carcinoma found at risk reducing salpingectomy in a BRCA1 carrier.
    • Kim SH, Frey MK, Blank SV.
    • Gynecol Oncol Case Rep. 2014 Apr 2;9:1-2. doi: 10.1016/j.gynor.2014.03.003. eCollection 2014.
    • Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations.
    • Conner JR, Meserve E, Pizer E, Garber J, Roh M, Urban N, Drescher C, Quade BJ, Muto M, Howitt BE, Pearlman MD, Berkowitz RS, Horowitz N, Crum CP, Feltmate C.
    • Gynecol Oncol. 2014 Feb;132(2):280-6. doi: 10.1016/j.ygyno.2013.12.009. Epub 2013 Dec 12.

    Comment/Editorial:

    Risk reducing salpingo-oophorectomy for BRCA mutation carriers: twenty years later.

    • Refractory fallopian tube carcinoma - current perspectives in pathogenesis and management.
    • Sama AR, Schilder RJ.
    • Int J Womens Health. 2014 Jan 28;6:149-57. doi: 10.2147/IJWH.S40889. eCollection 2014.
    • Biomarkers and endosalpingiosis in the ovarian and tubal microenvironment of women at high-risk for pelvic serous carcinoma.
    • Gruessner C, Gruessner A, Glaser K, Abushahin N, Laughren C, Zheng W, Chambers SK.
    • Am J Cancer Res. 2014 Jan 15;4(1):61-72. eCollection 2014.
    • BRCA1 and BRCA2 - update and implications on the genetics of breast cancer: a clinical perspective.
    • Foulkes W.
    • Clin Genet. 2014 Jan;85(1):1-4. doi: 10.1111/cge.12291. Epub 2013 Oct 25.
    • Editorial / Commentary
    • Clinical Outcome of Isolated Serous Tubal Intraepithelial Carcinomas (STIC).
    • Wethington SL, Park KJ, Soslow RA, Kauff ND, Brown CL, Dao F, Otegbeye E, Sonoda Y, Abu-Rustum NR, Barakat RR, Levine DA, Gardner GJ.
    • Int J Gynecol Cancer. 2013 Nov;23(9):1603-11. doi: 10.1097/IGC.0b013e3182a80ac8.
    • Pelvic Kidney in a BRCA-1-Positive Patient Undergoing Prophylactic Bilateral Salpingo-oophorectomy.
    • Brotherton J, Pedroso J.
    • J Minim Invasive Gynecol. 2013 Sep-Oct;20(5):547-8. doi: 10.1016/j.jmig.2013.01.017. Epub 2013 Apr 2.
    • Case report
    • Fallopian tube intraluminal tumor spread from noninvasive precursor lesions: a novel metastatic route in early pelvic carcinogenesis.
    • Bijron JG, Seldenrijk CA, Zweemer RP, Lange JG, Verheijen RH, van Diest PJ.
    • Am J Surg Pathol. 2013 Aug;37(8):1123-30. doi: 10.1097/PAS.0b013e318282da7f.
    • Case report

    Letter, Comment:

    Fallopian tube intraluminal tumor spread.

    Letter, Comment:

    Serous carcinogenesis: a classic causality dilemma or which came first... ?

    • Do deeper sections increase the frequency of detection of serous tubal intraepithelial carcinoma (STIC) in the "sectioning and extensively examining the FIMbriated end" (SEE-FIM) protocol?
    • Mahe E, Tang S, Deb P, Sur M, Lytwyn A, Daya D.
    • Int J Gynecol Pathol. 2013 Jul;32(4):353-7. doi: 10.1097/PGP.0b013e318264ae09.
    • Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesions.
    • Chene G, Tchirkov A, Pierre-Eymard E, Dauplat J, Raoelfils I, Cayre A, Watkin E, Vago P, Penault-Llorca F.
    • Clin Cancer Res. 2013 Jun 1;19(11):2873-82. doi: 10.1158/1078-0432.CCR-12-3947. Epub 2013 Apr 15.

    Letter, Comment:

    Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesions--letter.

    Letter, Reply:

    Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesions--response.

    • Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy.
    • Powell CB, Swisher EM, Cass I, McLennan J, Norquist B, Garcia RL, Lester J, Karlan BY, Chen L.
    • Gynecol Oncol. 2013 May;129(2):364-71. doi: 10.1016/j.ygyno.2013.01.029. Epub 2013 Feb 4.
    • Salpingectomy: Can removing the fallopian tubes lower ovarian cancer risk?
    • Ilana Cass, Doug Levine
    • FORCE. Be Empowered Webinars. 2013 Apr 11.
    • Serial sectioning of the fallopian tube allows for improved identification of primary fallopian tube carcinoma.
    • Lengyel E, Fleming S, McEwen KA, Montag A, Temkin SM.
    • Gynecol Oncol. 2013 Apr;129(1):120-3. doi: 10.1016/j.ygyno.2012.12.006. Epub 2012 Dec 10.
    • Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens.
    • Reitsma W, de Bock GH, Oosterwijk JC, Bart J, Hollema H, Mourits MJ.
    • Eur J Cancer. 2013 Jan;49(1):132-41. doi: 10.1016/j.ejca.2012.07.021. Epub 2012 Aug 21.
    • The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer: Is the evidence strong enough?
    • Haldar K, Crawford R.
    • Gynecol Oncol. 2013 Jan;128(1):148-9. doi: 10.1016/j.ygyno.2012.08.019. Epub 2012 Aug 20.
    • Comment, Letter

    Editorial:

    The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer.

    Letter, Reply:

    There is a need for routine peritoneal cytology at RRSO.

    • There is a need for routine peritoneal cytology at RRSO.
    • Manchanda R, Drapkin R, Menon U.
    • Gynecol Oncol. 2013 Jan;128(1):149-50. doi: 10.1016/j.ygyno.2012.09.031. Epub 2012 Oct 9.
    • Comment, Letter

    Letter, Comment:

    The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer: Is the evidence strong enough?

    Editorial:

    The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer.

    • Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls.
    • Mingels MJ, Roelofsen T, van der Laak JA, de Hullu JA, van Ham MA, Massuger LF, Bulten J, Bol M.
    • Gynecol Oncol. 2012 Oct;127(1):88-93. doi: 10.1016/j.ygyno.2012.06.015. Epub 2012 Jun 16.
    • Peritoneal cytology in risk-reducing salpingo-oophorectomy: Implications for cancer outcomes.
    • Chen L, McAlhaney S, Fehniger J, Powell C, Crawford B, Mak J, Rabban J.
    • Gynecol Oncol. 2012 Oct;127(1 Suppl):S17. doi: 10.1016/j.ygyno.2012.07.047.
    • Conference abstract
    • Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome.
    • This P, de la Rochefordière A, Savignoni A, Falcou MC, Tardivon A, Thibault F, Alran S, Fourchotte V, Fitoussi A, Couturaud B, Dolbeault S, Salmon RJ, Sigal-Zafrani B, Asselain B, Stoppa-Lyonnet D.
    • Fam Cancer. 2012 Sep;11(3):473-82. doi: 10.1007/s10689-012-9539-1.
    • Effectiveness of risk-reducing salpingo-oophorectomy in preventing ovarian cancer in a high-risk French Canadian population.
    • Bacha OM, Gregoire J, Grondin K, Edelweiss MI, Laframboise R, Simard J, Plante M.
    • Int J Gynecol Cancer. 2012 Jul;22(6):974-8. doi: 10.1097/IGC.0b013e318257b936.
    • Diathermy-induced injury may affect detection of occult tubal lesions at risk-reducing salpingo-oophorectomy.
    • Manchanda R, Silvanto A, Abdelraheim A, Burnell M, Johnson M, Saridogan E, Rosenthal AN, Brunell C, Aslam N, Vashisht A, Pandis G, Jacobs I, Menon U, Benjamin E.
    • Int J Gynecol Cancer. 2012 Jun;22(5):881-8. doi: 10.1097/IGC.0b013e31824b4093.
    • The role of the fallopian tube in ovarian cancer.
    • Tone AA, Salvador S, Finlayson SJ, Tinker AV, Kwon JS, Lee CH, Cohen T, Ehlen T, Lee M, Carey MS, Heywood M, Pike J, Hoskins PJ, Stuart GC, Swenerton KD, Huntsman DG, Gilks CB, Miller DM, McAlpine JN.
    • Clin Adv Hematol Oncol. 2012 May;10(5):296-306.
    • BRCA, the oviduct, and the space and time continuum of pelvic serous carcinogenesis.
    • Crum CP, McKeon FD, Xian W.
    • Int J Gynecol Cancer. 2012 May;22 Suppl 1:S29-34. doi: 10.1097/IGC.0b013e31824d7269.
    • Impact of lifestyle factors on preneoplastic changes in prophylactic oophorectomies of BRCA mutation carriers.
    • Primas H, Kroiss R, Kalteis K, Rappaport C, Muhr D, Primas C, Kubista E, Horvat R, Oefner P, Singer C, Wagner And The Austrian Hereditary Breast And Ovarian Cancer Group T.
    • Eur J Cancer Prev. 2012 Mar;21(2):199-204. doi: 10.1097/CEJ.0b013e32834c9b22.
    • The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer.
    • Manchanda R, Drapkin R, Jacobs I, Menon U.
    • Gynecol Oncol. 2012 Feb;124(2):185-91. doi: 10.1016/j.ygyno.2011.10.017. Epub 2011 Oct 20.
    • Commentary

    Comment, Letter:

    The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer: Is the evidence strong enough?

    Comment, Letter:

    There is a need for routine peritoneal cytology at RRSO.

    • [Don't forget fallopian tubes! A morphologic and immunohistochemical study about Fallopian tubes with genetic risk (BRCA mutation)].
    • Chêne G, Raoelfils I, Cayre A, Dauplat J, Bignon YJ, Jaffeux P, Aublet-Cuvelier B, Penault-Llorca F.
    • Gynecol Obstet Fertil. 2012 Jan;40(1):14-8. doi: 10.1016/j.gyobfe.2011.07.043. Epub 2011 Oct 21.
    • [Article in French]